https://www.selleckchem.com/pr....oducts/phosphoramido
4% vs. 16.5%, = 0.985) but a significantly lower rate of MT (3.8% vs. 7.9%, = 0.017). In-hospital mortality rate was significantly higher in patients with AIS and concurrent Covid-19 compared to non-infected AIS patients (22.5% vs. 7.8%, 0.001). These nationwide data point out differences in mortality and medical treatment regime between AIS patients with and without concurrent Covid-19. Since the pandemic is still ongoing, these data draw attention to AIS as a less frequent but often fatal comorbidity in Co
Beğen
Yorum Yap
Paylaş
